Cargando…
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
Hypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this antitumour drug. Administration of histamine H1- and H2-receptor antagonists and corticosteroids has been shown to reduce significantly the risk of developing an HSR in patients receiving taxanes. I...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2004
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409560/ https://www.ncbi.nlm.nih.gov/pubmed/14974481 http://dx.doi.org/10.1038/sj.bjc.6601303 |